Medullary Thyroid Cancer - Pipeline Review, H2 2016


#816177

100pages

Global Markets Direct

$ 2000

In Stock

Medullary Thyroid Cancer - Pipeline Review, H2 2016

Summary

Global Markets Directs, Medullary Thyroid Cancer - Pipeline Review, H2 2016, provides an overview of the Medullary Thyroid Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Medullary Thyroid Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Medullary Thyroid Cancer and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Medullary Thyroid Cancer
- The report reviews pipeline therapeutics for Medullary Thyroid Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Medullary Thyroid Cancer therapeutics and enlists all their major and minor projects
- The report assesses Medullary Thyroid Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Medullary Thyroid Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Medullary Thyroid Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Medullary Thyroid Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Medullary Thyroid Cancer Overview 8
Therapeutics Development 9
Pipeline Products for Medullary Thyroid Cancer - Overview 9
Pipeline Products for Medullary Thyroid Cancer - Comparative Analysis 10
Medullary Thyroid Cancer - Therapeutics under Development by Companies 11
Medullary Thyroid Cancer - Therapeutics under Investigation by Universities/Institutes 12
Medullary Thyroid Cancer - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Medullary Thyroid Cancer - Products under Development by Companies 16
Medullary Thyroid Cancer - Products under Investigation by Universities/Institutes 17
Medullary Thyroid Cancer - Companies Involved in Therapeutics Development 18
AbbVie Inc 18
Advenchen Laboratories, LLC 19
Bayer AG 20
Boehringer Ingelheim GmbH 21
Celgene Corporation 22
Hutchison MediPharma Limited 23
Immunomedics, Inc. 24
Nerviano Medical Sciences S.r.l. 25
Novartis AG 26
Pfizer Inc. 27
Medullary Thyroid Cancer - Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Target 29
Assessment by Mechanism of Action 32
Assessment by Route of Administration 35
Assessment by Molecule Type 37
Drug Profiles 39
AL-3818 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
CLM-29 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
CLM-3 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
CLM-94 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
everolimus - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
GI-6207 - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
HMPL-012 - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
nintedanib - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
NMS-616 - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
pasireotide - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
regorafenib - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
rovalpituzumab tesirine - Drug Profile 87
Product Description 87
Mechanism Of Action 87
R&D Progress 87
Small Molecule 1 to Inhibit RET Receptor Tyrosine Kinase for Medullary Thyroid Cancer - Drug Profile 89
Product Description 89
Mechanism Of Action 89
R&D Progress 89
Small Molecule to Inhibit RET Receptor Tyrosine Kinase for Medullary Thyroid Cancer - Drug Profile 90
Product Description 90
Mechanism Of Action 90
R&D Progress 90
SYN-001 - Drug Profile 91
Product Description 91
Mechanism Of Action 91
R&D Progress 91
temsirolimus - Drug Profile 92
Product Description 92
Mechanism Of Action 92
R&D Progress 92
TF-2 - Drug Profile 94
Product Description 94
Mechanism Of Action 94
R&D Progress 94
Medullary Thyroid Cancer - Dormant Projects 96
Medullary Thyroid Cancer - Discontinued Products 97
Medullary Thyroid Cancer - Product Development Milestones 98
Featured News & Press Releases 98
Apr 03, 2013: GlobeImmune Initiates Phase II Study Of New T Cell Stimulating Cancer Vaccine Targeting CEA In Patients With Metastatic Medullary Thyroid Cancer 98
Appendix 99
Methodology 99
Coverage 99
Secondary Research 99
Primary Research 99
Expert Panel Validation 99
Contact Us 99
Disclaimer 100

List of Tables
Number of Products under Development for Medullary Thyroid Cancer, H2 2016 9
Number of Products under Development for Medullary Thyroid Cancer - Comparative Analysis, H2 2016 10
Number of Products under Development by Companies, H2 2016 11
Number of Products under Investigation by Universities/Institutes, H2 2016 12
Comparative Analysis by Late Stage Development, H2 2016 13
Comparative Analysis by Clinical Stage Development, H2 2016 14
Comparative Analysis by Early Stage Development, H2 2016 15
Products under Development by Companies, H2 2016 16
Products under Investigation by Universities/Institutes, H2 2016 17
Medullary Thyroid Cancer - Pipeline by AbbVie Inc, H2 2016 18
Medullary Thyroid Cancer - Pipeline by Advenchen Laboratories, LLC, H2 2016 19
Medullary Thyroid Cancer - Pipeline by Bayer AG, H2 2016 20
Medullary Thyroid Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016 21
Medullary Thyroid Cancer - Pipeline by Celgene Corporation, H2 2016 22
Medullary Thyroid Cancer - Pipeline by Hutchison MediPharma Limited, H2 2016 23
Medullary Thyroid Cancer - Pipeline by Immunomedics, Inc., H2 2016 24
Medullary Thyroid Cancer - Pipeline by Nerviano Medical Sciences S.r.l., H2 2016 25
Medullary Thyroid Cancer - Pipeline by Novartis AG, H2 2016 26
Medullary Thyroid Cancer - Pipeline by Pfizer Inc., H2 2016 27
Assessment by Monotherapy Products, H2 2016 28
Number of Products by Stage and Target, H2 2016 30
Number of Products by Stage and Mechanism of Action, H2 2016 33
Number of Products by Stage and Route of Administration, H2 2016 36
Number of Products by Stage and Molecule Type, H2 2016 38
Medullary Thyroid Cancer - Dormant Projects, H2 2016 96
Medullary Thyroid Cancer - Discontinued Products, H2 2016 97

List of Figures
Number of Products under Development for Medullary Thyroid Cancer, H2 2016 9
Number of Products under Development for Medullary Thyroid Cancer - Comparative Analysis, H2 2016 10
Number of Products under Development by Companies, H2 2016 11
Number of Products under Investigation by Universities/Institutes, H2 2016 12
Comparative Analysis by Early Stage Products, H2 2016 15
Assessment by Monotherapy Products, H2 2016 28
Number of Products by Top 10 Targets, H2 2016 29
Number of Products by Stage and Top 10 Targets, H2 2016 29
Number of Products by Top 10 Mechanism of Actions, H2 2016 32
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 32
Number of Products by Routes of Administration, H2 2016 35
Number of Products by Stage and Routes of Administration, H2 2016 35
Number of Products by Molecule Types, H2 2016 37
Number of Products by Stage and Molecule Types, H2 2016 37